Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.
Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.
EQ, Inc. ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial ownership of 6,480,209 shares, representing 9.9% of the outstanding common stock under a Beneficial Ownership Blocker.
The 9.9% figure is calculated using November 10, 2025 outstanding shares of 60,893,283, plus 1,179,508 shares issued in a private placement on March 13, 2026, and 3,383,873 shares issuable upon exercise of pre-funded warrants. The Fund holds 3,096,336 shares directly and pre-funded warrants exercisable for up to 17,698,593 shares; exercise is blocked to prevent ownership above 9.9%.
Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised options to acquire 120,312 shares of common stock at an exercise price of $0.785 per share. She then sold 120,312 shares of common stock at a weighted average price of $2.5003 per share in open-market transactions effected under a Rule 10b5-1 trading plan adopted on August 27, 2025. Following these transactions, she directly holds 62,586 shares of Equillium common stock. The option exercised had been scheduled to vest over four years, with 25% on the first anniversary and the remainder in 36 equal monthly installments.
Form 144 notice: Christine Zedelmayer submitted a Rule 144 notice reporting proposed sales of Common Stock. The filing lists a proposed sale quantity of 120,312 shares dated 03/13/2026, and shows prior reported dispositions of 11,900 shares on 12/15/2025, 185,937 shares on 02/19/2026, and 181,219 shares on 03/09/2026.
Equillium, Inc. entered into a private placement with RA Capital Healthcare Fund to raise approximately $35.0 million through common stock and a pre-funded warrant. The company will sell 1,179,508 shares at $1.854 per share and a pre-funded warrant for up to 17,698,593 shares at $1.8539 per warrant share, with an exercise price of $0.0001 per share. The warrant is exercisable immediately on a cash or cashless basis, subject to a beneficial ownership cap of 19.99%. Equillium plans to use the net proceeds, together with existing cash, to fund development of EQ504 and for working capital and general corporate purposes. The company will also grant the investor registration rights to resell the shares and warrant shares, subject to potential cash penalties if registration obligations are not met.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported an exercise-and-sell set of transactions in company common stock. On February 19, 2026, she exercised options to acquire a total of 185,937 shares of common stock at prices of $0.785 and $0.73 per share.
On the same date, she sold the same 185,937 shares in open-market transactions at average prices of about $1.78 per share. After these trades, she directly held 91,444 shares of Equillium common stock. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025, indicating they were pre-arranged rather than timed discretionarily.
Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised stock options and sold shares in a planned transaction. On March 9, 2026 she exercised options for a total of 152,361 shares of common stock at an exercise price of $0.785 per share.
The same day she sold 181,219 shares of common stock at a weighted average price of $2.00 per share, with individual sale prices ranging from $2.00 to $2.015, under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions she directly owned 62,586 shares of Equillium common stock.
Christine Zedelmayer reported sales of common stock under Rule 144. The filing lists four transactions dated 11/25/2025, 12/12/2025, 12/15/2025, and 02/19/2026 totaling 229,739 shares sold for aggregate proceeds of $377,658.
The transactions are reported on Form 144 and reflect dispositions from stock option-related and employee plan holdings referenced in the securities table.
Equillium, Inc. executive Christine Zedelmayer reported option exercises and related share sales in a Form 4. On February 19, 2026, she exercised employee stock options covering 109,375 and 76,562 shares, converting them into common stock at stated exercise prices.
On the same date, she sold 109,375 shares at $1.7814 per share and 76,562 shares at $1.7406 per share in open-market transactions. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions, she directly owned 191,444 shares of Equillium common stock.
EQ reported insider sales via Form 144 by Christine Zedelmayer. The filing lists multiple reported dispositions of Common Stock on 11/25/2025 (8,098 shares, $7,696.00), 12/12/2025 (23,804 shares, $31,897.00), 12/15/2025 (11,900 shares, $15,589.00), and 12/23/2025 (100,000 shares, $150,000.00).
The filing also lists planned sales of Common Stock issuable upon exercise of stock options dated 01/12/2022 (109,375 shares) and 01/02/2024 (76,562 shares), with sale method indicated as Cash.
Janus Henderson Group plc has filed an amended Schedule 13G reporting beneficial ownership of 6,083,239 shares of Equillium, Inc. common stock, representing 9.99% of the class. These holdings are managed through various affiliated asset managers on behalf of client accounts, called Managed Portfolios.
The position includes shares that may be obtained through exercise of certain pre-funded warrants that are exercisable within 60 days, but only to the extent total beneficial ownership does not exceed 9.99% of Equillium’s outstanding common stock. An additional 18,584,856 warrants are excluded from the reported figures due to this ownership cap. Dividends and sale proceeds belong to the Managed Portfolios, not Janus Henderson.